^
Association details:
| Biomarker: | IDH2 mutation + NRAS mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | dubermatinib (TP-0903) (AXL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TP-0903 is active in models of drug-resistant acute myeloid leukemia
Published date:
12/03/2020
Excerpt:
TP-0903 demonstrated preclinical activity in AML models with FLT3-ITD and common co-occurring mutations in IDH2 and NRAS genes.
DOI:
10.1172/jci.insight.140169
